Citius Oncology, Inc. (CTOR) - 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended December 31, 2025. Citius Oncology, Inc. is a specialty biopharmaceutical company focused on the commercialization of LYMPHIR (denileukin diftitox), an approved immunotherapy for cutaneous T-cell lymphoma (CTCL). The company is a smaller reporting company and an emerging growth company. Revenue generation commenced in December 2025 following the commercial launch of LYMPHIR. The company is currently evaluating strategic alternatives and relies heavily on funding from its majority shareholder, Citius Pharmaceuticals, Inc. (Citius Pharma).
Key Financial Metrics
| Metric | Q1 2026 (Ended Dec 31, 2025) | Q1 2025 (Ended Dec 31, 2024) |
|---|---|---|
| Revenue | $3,944,111 | $0 |
| Gross Profit | $3,154,903 | $0 |
| Gross Margin | 80.0% | N/A |
| Net Loss | $(5,534,069) | $(6,659,205) |
| Operating Loss | $(5,252,276) | $(6,394,965) |
| Cash and Equivalents (End of Period) | $7,295,451 | $112 |
| Working Capital | $(7,563,550) | N/A |
| Total Liabilities | $51,559,705 | N/A |
| Stockholders' Equity | $58,413,701 | $41,289,612 |
Debt and Liquidity: The company holds a note payable to a related party (Citius Pharma) of $3,800,111. Current liabilities include $18,250,000 in license payables to Dr. Reddy's and significant amounts due to related parties ($11,494,578). Cash flow from operations was negative $7,354,946, offset by $15,125,489 in net proceeds from financing activities (equity offering).
Material Changes vs. Prior Period
- Revenue Initiation: The company recorded its first revenue of $3.9 million in Q1 2026, compared to zero in the prior year, driven by the December 2025 launch of LYMPHIR.
- Amortization: Amortization of in-process research and development (IPR&D) began in Q1 2026, totaling $573,438, as revenue generation commenced. This was $0 in the prior period.
- Stock-Based Compensation: Increased significantly to $3,956,050 from $1,808,478 in the prior year, primarily due to restricted stock awards granted in September 2025.
- Net Loss Reduction: Net loss decreased by approximately $1.1 million year-over-year, largely attributable to the new gross profit of $3.15 million, partially offset by higher operating expenses.
- Capital Raise: In December 2025, the company completed an offering raising approximately $15.1 million in net proceeds, significantly increasing cash balances from $3.9 million at the start of the quarter to $7.3 million.
Outlook, Risks, and Management Commentary
- Going Concern: The filing includes a substantial doubt about the company's ability to continue as a going concern. Management expects funds to last through May 2026. Additional capital will be required to support operations beyond this date.
- Strategic Alternatives: The company has retained Jefferies LLC as an exclusive financial advisor to evaluate strategic alternatives to maximize shareholder value.
- Outstanding Obligations: Significant milestone payments remain due, including $18.25 million to Dr. Reddy's (partially deferred) and approximately $6.8 million in unpaid invoices to Eisai. Minimum purchase commitments for manufacturing total approximately $16.2 million through 2026.
- Risks: Key risks include the ability to raise additional capital, dependence on Citius Pharma for funding, market acceptance of LYMPHIR, and compliance with Nasdaq listing requirements.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise given the May 2026 liquidity horizon.
- Milestone Payments: Confirm the payment schedule and terms for the $18.25 million owed to Dr. Reddy's and the $6.8 million owed to Eisai.
- Revenue Sustainability: Assess whether the initial $3.9 million revenue run rate is sustainable or if it represents a one-time launch spike.
- Related Party Dependence: Review the extent of reliance on Citius Pharma for funding and shared services, noting the $11.5 million due to related parties.
- Manufacturing Commitments: Evaluate the impact of the $16.2 million minimum purchase commitment on future cash flow if sales volumes do not meet expectations.